The synthesis and the structure-activity relationships of renin inhibitors designed from the angiotensinogen transition state are described. These inhibitors contained residues modified at P1-P1, , P2, and P4-P3. Decrease in the size of side chain alkyl group in norstatine analog at P1 diminished the inhibitory activities of the compounds. Compound 5j, which contained valine residue instead of histidine residue at P2, inhibited potently cathepsin D (IC50=6.0×10-9 M) and pepsin (IC50=3.5×10-7 M) to the same extent as renin (IC50=8.5×10-10 M), and thus was not specific for renin. The reduction of the β-carbonyl group to methylene group in β-carbonylpropionyl residue at P4-P3 decreased the potency about 2 orders against human renin (5i : IC50=1.1×10-7 M vs. 1 : IC50=2.4 ×10-9 M). These results confirmed the rationality of our analysis of the interaction between an orally potent human renin inhibitor 1 and the active site of human renin using modeling techniques, showing that 1 fits the active site of renin favorably. The experimental details of the synthesis are presented.
描述了基于
血管紧张素原过渡态设计的肾素
抑制剂的合成及其构效关系。这些
抑制剂在P1-P1、P2和P4-P3位点含有修饰的残基。在P1位点,诺斯他
酮类似物侧链烷基基团的尺寸减小,降低了化合物的抑制活性。化合物5j在P2位点含有缬
氨酸残基而非组
氨酸残基,能有效抑制猫hepsin D(IC50=6.0×10⁻⁹ M)和胃
蛋白酶(IC50=3.5×10⁻⁷ M),其抑制活性与肾素相当(IC50=8.5×10⁻¹⁰ M),因此并非特异性针对肾素。P4-P3处β-羰基基团减少为亚甲基基团,使其对人肾素的效能下降了约两个数量级(5i: IC50=1.1×10⁻⁷ M vs. 1: IC50=2.4×10⁻⁹ M)。这些结果证实了我们对口服有效的人肾素
抑制剂1与人肾素活性位点间相互作用的分析合理性,显示出1与肾素活性位点的适配良好。合成的实验细节也已呈现。